November 13, 2025 Sophia Vida
Breaking News

BioStem Technologies Announces Filing of Restated Financial Statements

Key Takeaways Restated Financials Filed — BioStem filed restated interim and annual financial statements for 2023–2025, aligning with US GAAP for revenue recognition. Revenue Classification Update — Bona fide services fees from Venture Medical are now treated as contra revenue, lowering gross sales but not impacting EBITDA or cash flow. Audit and Uplist Progress — … Continue reading “BioStem Technologies Announces Filing of Restated Financial Statements”